Sanofi Pursues Enhanced Bid for US Biotech Ocular Therapeutix
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.
/ 3 items
#OCUL↓
Ocular Therapeutix Stock Jumps 27% on Accelerated Drug Approval Plans
Ocular Therapeutix (OCUL) shares surge 27% after announcing plans to fast-track FDA submission for Axpaxli, a promising new treatment for wet age-related macular degeneration affecting millions.
Big Boost for Ocular Therapeutix Stock and Drug Forecast
Piper Sandler raised Ocular Therapeutix stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data.